Roy Fleischmann

Roy Fleischmann

Company: University of Texas Southwestern Medical Center

Job title: Co-Medical Director Metroplex Clinical Research Center, Clinical Professor of Medicine


Roy Fleischmann MD, MACR graduated from Columbia College in NYC and received his MD from the State University of New York, Downstate Medical Center. He completed his Fellowship in Rheumatology at the College of Physicians and Surgeons of Columbia University. He is a Clinical Professor of Medicine at Southwestern Medical Center in Dallas. Dr. Fleischmann has been the principal investigator and involved in the development of virtually all currently approved medications in many rheumatic diseases, primarily in RA. He helped develop the clinical programs for Pfizer, Lilly and AbbVie for their JAK inhibitors in RA and has published the results of many of these trials.


Live Discussion & Question Time 12:00 pm

What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases? How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints? In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how…Read more

day: Day One

What’s Been Right & Wrong in the Clinical Trial Programs of JAK Inhibitors for Rheumatoid Arthritis (RA) & What can be Improved? 11:40 am

What has been done correctly in each of the clinical trial programs for JAK inhibitors in RA? What could have been done better in each of the clinical trial programs for JAK inhibitors in RA? Suggestions for better clinical trial design of JAK inhibitors in RA with more meaningful resultsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.